Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Allied Market Research | PRODUCT CODE: 1566974

Cover Image

PUBLISHER: Allied Market Research | PRODUCT CODE: 1566974

Cytotoxic Drug Market By Drug Type , By Application By Route of Administration By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2024-2033

PUBLISHED:
PAGES: 245 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF (Business License)
USD 4425
PDF (Enterprise User License) & Excel (Data Pack) & Free Update
USD 7412

Add to Cart

The cytotoxic drug market was valued at $15.8 billion in 2023, and is projected to reach $19.5 billion by 2033, growing at a CAGR of 2.1% from 2024 to 2033.

Cytotoxic drugs are chemotherapeutic agents that inhibit the growth of cancer cells by acting directly on the DNA or interfering with the biosynthesis of proteins. However, because they also affect healthy cells that divide frequently, such as those in the bone marrow, digestive tract, and hair follicles, their use is often accompanied by significant side effects. Despite these challenges, cytotoxic drugs remain essential in the treatment of various cancers, contributing to improved survival rates and better management of the disease.

The growth of the global cytotoxic drug market is majorly driven by alarming increase prevalence of cancer. According to the World Health Organization, cancer is the leading cause of death, and accounted for approximately 10 million deaths in 2020, thus fueling the demand for effective chemotherapy treatments, including cytotoxic drugs. Moreover, surge in geriatric population significantly contributes toward the growth of the global market. This is attributed to the fact that aged individuals are highly susceptible to cancer, leading to higher demand for cancer treatments. Furthermore, rise in awareness about early detection and treatment of cancer acts as the key driving force of the market. The American Cancer Society highlights that the five-year survival rate for cancer patients diagnosed at an early stage is 90%, compared to 20% for those diagnosed at a later stage, thereby highlighting the importance of early detection and the consequent use of cytotoxic drugs in treatment. Rise in emphasis on developing targeted cytotoxic therapies tailored to individual patients' genetic profiles to improve treatment efficacy and minimize side effects is further propelling the market growth. In addition, oral cytotoxic drugs are gaining high traction due to their convenience and ease of administration, allowing for better patient compliance and quality of life, thus augmenting the market growth. However, adverse effects associated with cytotoxic drugs, such as nausea, hair loss, and bone marrow suppression, limit their use, which hampers the growth of the global market. In addition, rise in awareness about more effective therapies such as targeted therapies, immunotherapies, and other innovative cancer treatments potentially reduce the demand for traditional cytotoxic drugs, which acts as the key deterrent factor of the market. On the contrary, innovations in drug formulation and delivery systems to enhance the efficacy and safety of cytotoxic drugs are expected to offer lucrative opportunities for the growth of the global market during the forecast period. For instance, recent studies have shown that new formulations of cytotoxic drugs, such as liposomal doxorubicin, can reduce side effects and improve patient outcomes. Clinical trials have demonstrated that these advanced formulations can enhance drug delivery to tumor sites by 30-40%.

The global cytotoxic drug market is segmented into drug type, application, route of administration, distribution channel, and region. On the basis of the drug type, the market is segregated into alkylating agents, antitumor antibiotics, antimetabolites, plant alkaloids, and others. As per application, it is classified into breast cancer, prostate cancer, lung cancer, pancreatic cancer, and others. By route of administration, it is bifurcated into oral and parenteral. According to distribution channel, it is fragmented into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By drug type, the antimetabolites segment is expected to dominate the market by 2033.

On the basis of application, breast cancer is anticipated to emerge as a leading segment during the forecast period.

Depending on route of administration, the oral segment is projected to exhibit the highest growth in the coming years.

As per distribution channel, the hospital pharmacies segment is likely to lead the lobal cytotoxic drug market in the near future.

Region wise, North America was the major shareholder in the cytotoxic drug market in 2023, and is expected to retain its dominance throughout the forecast period.

Competition Analysis

Competitive analysis and profiles of the major players in the global cytotoxic drug market include Baxter, Cipla Ltd, Eli Lilly and Company, Fresenius Kabi AG, Johnson & Johnson, Novartis AG, Viatris Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and strengthen their foothold in the global market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Drug Type

  • Alkylating Agents
  • Antitumor Antibiotics
  • Antimetabolites
  • Plant Alkaloids
  • Others

By Application

  • Breast Cancer
  • Prostate Cancer
  • Lung Cancer
  • Pancreatic Cancer
  • Others

By Route Of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Baxter
    • Cipla Ltd
    • Eli Lilly and Company
    • Fresenius Kabi AG
    • Johnson & Johnson
    • Novartis AG
    • Viatris Inc.
    • Pfizer Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Teva Pharmaceutical Industries Ltd.
Product Code: A324399

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: CYTOTOXIC DRUG MARKET, BY DRUG TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Drug Type
  • 4.2. Alkylating Agents
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Antitumor Antibiotics
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Antimetabolites
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country
  • 4.5. Plant Alkaloids
    • 4.5.1. Key Market Trends, Growth Factors and Opportunities
    • 4.5.2. Market Size and Forecast, By Region
    • 4.5.3. Market Share Analysis, By Country
  • 4.6. Others
    • 4.6.1. Key Market Trends, Growth Factors and Opportunities
    • 4.6.2. Market Size and Forecast, By Region
    • 4.6.3. Market Share Analysis, By Country

CHAPTER 5: CYTOTOXIC DRUG MARKET, BY APPLICATION

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Application
  • 5.2. Breast Cancer
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Prostate Cancer
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Lung Cancer
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country
  • 5.5. Pancreatic Cancer
    • 5.5.1. Key Market Trends, Growth Factors and Opportunities
    • 5.5.2. Market Size and Forecast, By Region
    • 5.5.3. Market Share Analysis, By Country
  • 5.6. Others
    • 5.6.1. Key Market Trends, Growth Factors and Opportunities
    • 5.6.2. Market Size and Forecast, By Region
    • 5.6.3. Market Share Analysis, By Country

CHAPTER 6: CYTOTOXIC DRUG MARKET, BY ROUTE OF ADMINISTRATION

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Route of Administration
  • 6.2. Oral
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Parenteral
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country

CHAPTER 7: CYTOTOXIC DRUG MARKET, BY DISTRIBUTION CHANNEL

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Distribution Channel
  • 7.2. Hospital Pharmacies
    • 7.2.1. Key Market Trends, Growth Factors and Opportunities
    • 7.2.2. Market Size and Forecast, By Region
    • 7.2.3. Market Share Analysis, By Country
  • 7.3. Drug Stores And Retail Pharmacies
    • 7.3.1. Key Market Trends, Growth Factors and Opportunities
    • 7.3.2. Market Size and Forecast, By Region
    • 7.3.3. Market Share Analysis, By Country
  • 7.4. Online Providers
    • 7.4.1. Key Market Trends, Growth Factors and Opportunities
    • 7.4.2. Market Size and Forecast, By Region
    • 7.4.3. Market Share Analysis, By Country

CHAPTER 8: CYTOTOXIC DRUG MARKET, BY REGION

  • 8.1. Market Overview
    • 8.1.1 Market Size and Forecast, By Region
  • 8.2. North America
    • 8.2.1. Key Market Trends and Opportunities
    • 8.2.2. Market Size and Forecast, By Drug Type
    • 8.2.3. Market Size and Forecast, By Application
    • 8.2.4. Market Size and Forecast, By Route of Administration
    • 8.2.5. Market Size and Forecast, By Distribution Channel
    • 8.2.6. Market Size and Forecast, By Country
    • 8.2.7. U.S. Cytotoxic Drug Market
      • 8.2.7.1. Market Size and Forecast, By Drug Type
      • 8.2.7.2. Market Size and Forecast, By Application
      • 8.2.7.3. Market Size and Forecast, By Route of Administration
      • 8.2.7.4. Market Size and Forecast, By Distribution Channel
    • 8.2.8. Canada Cytotoxic Drug Market
      • 8.2.8.1. Market Size and Forecast, By Drug Type
      • 8.2.8.2. Market Size and Forecast, By Application
      • 8.2.8.3. Market Size and Forecast, By Route of Administration
      • 8.2.8.4. Market Size and Forecast, By Distribution Channel
    • 8.2.9. Mexico Cytotoxic Drug Market
      • 8.2.9.1. Market Size and Forecast, By Drug Type
      • 8.2.9.2. Market Size and Forecast, By Application
      • 8.2.9.3. Market Size and Forecast, By Route of Administration
      • 8.2.9.4. Market Size and Forecast, By Distribution Channel
  • 8.3. Europe
    • 8.3.1. Key Market Trends and Opportunities
    • 8.3.2. Market Size and Forecast, By Drug Type
    • 8.3.3. Market Size and Forecast, By Application
    • 8.3.4. Market Size and Forecast, By Route of Administration
    • 8.3.5. Market Size and Forecast, By Distribution Channel
    • 8.3.6. Market Size and Forecast, By Country
    • 8.3.7. Germany Cytotoxic Drug Market
      • 8.3.7.1. Market Size and Forecast, By Drug Type
      • 8.3.7.2. Market Size and Forecast, By Application
      • 8.3.7.3. Market Size and Forecast, By Route of Administration
      • 8.3.7.4. Market Size and Forecast, By Distribution Channel
    • 8.3.8. France Cytotoxic Drug Market
      • 8.3.8.1. Market Size and Forecast, By Drug Type
      • 8.3.8.2. Market Size and Forecast, By Application
      • 8.3.8.3. Market Size and Forecast, By Route of Administration
      • 8.3.8.4. Market Size and Forecast, By Distribution Channel
    • 8.3.9. UK Cytotoxic Drug Market
      • 8.3.9.1. Market Size and Forecast, By Drug Type
      • 8.3.9.2. Market Size and Forecast, By Application
      • 8.3.9.3. Market Size and Forecast, By Route of Administration
      • 8.3.9.4. Market Size and Forecast, By Distribution Channel
    • 8.3.10. Italy Cytotoxic Drug Market
      • 8.3.10.1. Market Size and Forecast, By Drug Type
      • 8.3.10.2. Market Size and Forecast, By Application
      • 8.3.10.3. Market Size and Forecast, By Route of Administration
      • 8.3.10.4. Market Size and Forecast, By Distribution Channel
    • 8.3.11. Spain Cytotoxic Drug Market
      • 8.3.11.1. Market Size and Forecast, By Drug Type
      • 8.3.11.2. Market Size and Forecast, By Application
      • 8.3.11.3. Market Size and Forecast, By Route of Administration
      • 8.3.11.4. Market Size and Forecast, By Distribution Channel
    • 8.3.12. Rest of Europe Cytotoxic Drug Market
      • 8.3.12.1. Market Size and Forecast, By Drug Type
      • 8.3.12.2. Market Size and Forecast, By Application
      • 8.3.12.3. Market Size and Forecast, By Route of Administration
      • 8.3.12.4. Market Size and Forecast, By Distribution Channel
  • 8.4. Asia-Pacific
    • 8.4.1. Key Market Trends and Opportunities
    • 8.4.2. Market Size and Forecast, By Drug Type
    • 8.4.3. Market Size and Forecast, By Application
    • 8.4.4. Market Size and Forecast, By Route of Administration
    • 8.4.5. Market Size and Forecast, By Distribution Channel
    • 8.4.6. Market Size and Forecast, By Country
    • 8.4.7. Japan Cytotoxic Drug Market
      • 8.4.7.1. Market Size and Forecast, By Drug Type
      • 8.4.7.2. Market Size and Forecast, By Application
      • 8.4.7.3. Market Size and Forecast, By Route of Administration
      • 8.4.7.4. Market Size and Forecast, By Distribution Channel
    • 8.4.8. China Cytotoxic Drug Market
      • 8.4.8.1. Market Size and Forecast, By Drug Type
      • 8.4.8.2. Market Size and Forecast, By Application
      • 8.4.8.3. Market Size and Forecast, By Route of Administration
      • 8.4.8.4. Market Size and Forecast, By Distribution Channel
    • 8.4.9. India Cytotoxic Drug Market
      • 8.4.9.1. Market Size and Forecast, By Drug Type
      • 8.4.9.2. Market Size and Forecast, By Application
      • 8.4.9.3. Market Size and Forecast, By Route of Administration
      • 8.4.9.4. Market Size and Forecast, By Distribution Channel
    • 8.4.10. Australia Cytotoxic Drug Market
      • 8.4.10.1. Market Size and Forecast, By Drug Type
      • 8.4.10.2. Market Size and Forecast, By Application
      • 8.4.10.3. Market Size and Forecast, By Route of Administration
      • 8.4.10.4. Market Size and Forecast, By Distribution Channel
    • 8.4.11. South Korea Cytotoxic Drug Market
      • 8.4.11.1. Market Size and Forecast, By Drug Type
      • 8.4.11.2. Market Size and Forecast, By Application
      • 8.4.11.3. Market Size and Forecast, By Route of Administration
      • 8.4.11.4. Market Size and Forecast, By Distribution Channel
    • 8.4.12. Rest of Asia-Pacific Cytotoxic Drug Market
      • 8.4.12.1. Market Size and Forecast, By Drug Type
      • 8.4.12.2. Market Size and Forecast, By Application
      • 8.4.12.3. Market Size and Forecast, By Route of Administration
      • 8.4.12.4. Market Size and Forecast, By Distribution Channel
  • 8.5. LAMEA
    • 8.5.1. Key Market Trends and Opportunities
    • 8.5.2. Market Size and Forecast, By Drug Type
    • 8.5.3. Market Size and Forecast, By Application
    • 8.5.4. Market Size and Forecast, By Route of Administration
    • 8.5.5. Market Size and Forecast, By Distribution Channel
    • 8.5.6. Market Size and Forecast, By Country
    • 8.5.7. Brazil Cytotoxic Drug Market
      • 8.5.7.1. Market Size and Forecast, By Drug Type
      • 8.5.7.2. Market Size and Forecast, By Application
      • 8.5.7.3. Market Size and Forecast, By Route of Administration
      • 8.5.7.4. Market Size and Forecast, By Distribution Channel
    • 8.5.8. Saudi Arabia Cytotoxic Drug Market
      • 8.5.8.1. Market Size and Forecast, By Drug Type
      • 8.5.8.2. Market Size and Forecast, By Application
      • 8.5.8.3. Market Size and Forecast, By Route of Administration
      • 8.5.8.4. Market Size and Forecast, By Distribution Channel
    • 8.5.9. South Africa Cytotoxic Drug Market
      • 8.5.9.1. Market Size and Forecast, By Drug Type
      • 8.5.9.2. Market Size and Forecast, By Application
      • 8.5.9.3. Market Size and Forecast, By Route of Administration
      • 8.5.9.4. Market Size and Forecast, By Distribution Channel
    • 8.5.10. Rest of LAMEA Cytotoxic Drug Market
      • 8.5.10.1. Market Size and Forecast, By Drug Type
      • 8.5.10.2. Market Size and Forecast, By Application
      • 8.5.10.3. Market Size and Forecast, By Route of Administration
      • 8.5.10.4. Market Size and Forecast, By Distribution Channel

CHAPTER 9: COMPETITIVE LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top Winning Strategies
  • 9.3. Product Mapping of Top 10 Player
  • 9.4. Competitive Dashboard
  • 9.5. Competitive Heatmap
  • 9.6. Top Player Positioning, 2023

CHAPTER 10: COMPANY PROFILES

  • 10.1. Baxter
    • 10.1.1. Company Overview
    • 10.1.2. Key Executives
    • 10.1.3. Company Snapshot
    • 10.1.4. Operating Business Segments
    • 10.1.5. Product Portfolio
    • 10.1.6. Business Performance
    • 10.1.7. Key Strategic Moves and Developments
  • 10.2. Cipla Ltd
    • 10.2.1. Company Overview
    • 10.2.2. Key Executives
    • 10.2.3. Company Snapshot
    • 10.2.4. Operating Business Segments
    • 10.2.5. Product Portfolio
    • 10.2.6. Business Performance
    • 10.2.7. Key Strategic Moves and Developments
  • 10.3. Eli Lilly And Company
    • 10.3.1. Company Overview
    • 10.3.2. Key Executives
    • 10.3.3. Company Snapshot
    • 10.3.4. Operating Business Segments
    • 10.3.5. Product Portfolio
    • 10.3.6. Business Performance
    • 10.3.7. Key Strategic Moves and Developments
  • 10.4. Fresenius Kabi AG
    • 10.4.1. Company Overview
    • 10.4.2. Key Executives
    • 10.4.3. Company Snapshot
    • 10.4.4. Operating Business Segments
    • 10.4.5. Product Portfolio
    • 10.4.6. Business Performance
    • 10.4.7. Key Strategic Moves and Developments
  • 10.5. Johnson And Johnson
    • 10.5.1. Company Overview
    • 10.5.2. Key Executives
    • 10.5.3. Company Snapshot
    • 10.5.4. Operating Business Segments
    • 10.5.5. Product Portfolio
    • 10.5.6. Business Performance
    • 10.5.7. Key Strategic Moves and Developments
  • 10.6. Novartis AG
    • 10.6.1. Company Overview
    • 10.6.2. Key Executives
    • 10.6.3. Company Snapshot
    • 10.6.4. Operating Business Segments
    • 10.6.5. Product Portfolio
    • 10.6.6. Business Performance
    • 10.6.7. Key Strategic Moves and Developments
  • 10.7. Viatris Inc.
    • 10.7.1. Company Overview
    • 10.7.2. Key Executives
    • 10.7.3. Company Snapshot
    • 10.7.4. Operating Business Segments
    • 10.7.5. Product Portfolio
    • 10.7.6. Business Performance
    • 10.7.7. Key Strategic Moves and Developments
  • 10.8. Pfizer Inc.
    • 10.8.1. Company Overview
    • 10.8.2. Key Executives
    • 10.8.3. Company Snapshot
    • 10.8.4. Operating Business Segments
    • 10.8.5. Product Portfolio
    • 10.8.6. Business Performance
    • 10.8.7. Key Strategic Moves and Developments
  • 10.9. Sun Pharmaceutical Industries Ltd.
    • 10.9.1. Company Overview
    • 10.9.2. Key Executives
    • 10.9.3. Company Snapshot
    • 10.9.4. Operating Business Segments
    • 10.9.5. Product Portfolio
    • 10.9.6. Business Performance
    • 10.9.7. Key Strategic Moves and Developments
  • 10.10. Teva Pharmaceutical Industries Ltd.
    • 10.10.1. Company Overview
    • 10.10.2. Key Executives
    • 10.10.3. Company Snapshot
    • 10.10.4. Operating Business Segments
    • 10.10.5. Product Portfolio
    • 10.10.6. Business Performance
    • 10.10.7. Key Strategic Moves and Developments
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!